This inventor holds 1 USPTO granted patent and 5 published patent applications and 1 EPO patent. Top assignees: Centre National De La Recherche Scientifique, Ecole Superieure De Physique Et De Chimie Industrielles De La Ville De Paris, National Institute of Health and Medical Research. Active years: 2024.
Company Filing History:
1 out of 5,383 
1 out of 105 
1 out of 1,853 
Years Active: 2024
Title: Joëlle Vinh: Innovator in Type 1 Diabetes Research
Introduction
Joëlle Vinh is a prominent inventor based in Paris, France. He has made significant contributions to the field of diabetes research, particularly in understanding the mechanisms behind type 1 diabetes (T1D). His innovative work has led to the development of novel diagnostic and therapeutic approaches.
Latest Patents
Joëlle Vinh holds a patent for "Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes." This patent addresses the role of human CD8T cells in autoimmune β-cell destruction in T1D. The research revealed that urocortin 3 is a novel β-cell antigen, which is processed into HLA-A2- and HLA-A3-restricted epitopes. These epitopes are recognized by circulating naive CD8T cells in both type 1 diabetic and healthy donors. The invention provides a promising avenue for the diagnosis and treatment of T1D.
Career Highlights
Throughout his career, Joëlle Vinh has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de Paris. His research has focused on the intersection of immunology and diabetes, contributing to a deeper understanding of the disease.
Collaborations
Joëlle has collaborated with notable colleagues, including Roberto Mallone and Sergio Gonzalez-Duque. These partnerships have enhanced the scope and impact of his research in the field of diabetes.
Conclusion
Joëlle Vinh's innovative work in the realm of type 1 diabetes research exemplifies the importance of scientific inquiry in developing new diagnostic and therapeutic strategies. His contributions continue to pave the way for advancements in understanding and treating this complex disease.